Highlights Nxera Pharma Co., Ltd.

Equities

4565

JP3431300007

Market Closed - Japan Exchange Other stock markets 11:30:00 15/05/2024 am IST			5-day change	1st Jan Change
1,501 ^JPY	-3.91%		-2.91%	+5.63%

18/04	Nxera Pharma Initiates Restricted Stock Unit Plans, Starting with Shares Worth 164 Million Yen in Total in May	MT
17/04	Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test	17/04	MT
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568	16/04	CI
Nxera Pharma Partners with Handok c. to Distribute PIVLAZ in South Korea,	16/04	MT
Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for Pivlaz in South Korea	15/04	CI
Sosei Shareholders Greenlight Name Change, Top Management Appointments	28/03	MT
Sosei Group Corporation Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease	21/03	CI
Sosei Group Corporation Doses First Subject in a Phase 1 Trial Evaluating its Novel EP4 Receptor Agonist, HTL0033744 (HTL'744) for the Treatment of Inflammatory Bowel Disease	21/03	CI
Sosei Group, Boehringer Ingelheim Enter Into License Deal for Schizophrenia Symptoms	12/03	MT
Boehringer Ingelheim and Sosei Heptares Join Forces to Develop First-In-Class Treatments Targeting All Symptoms of Schizophrenia	11/03	CI
Boehringer Ingelheim and Sosei Group Corporation Enter Exclusive Option-To- License Agreement	11/03	CI
Sosei Group Corporation to Receive $2.5 Million Payment from Formosa Pharmaceuticals	06/03	CI
Drugmakers deepen efforts to tap into booming market for obesity drugs	27/02	RE
Sosei Group Corporation Announces Marketing Approval for PIVLAZ (Clazosentan Sodium) 150 Mg in South Korea	07/12	CI
Roche enters obesity drugs race with $2.7 bln Carmot deal	04/12	RE
Roche enters obesity drugs race with $2.7 bln Carmot deal	04/12	RE
Sosei Heptares and Kallyope Nominate First Gpcr Target for Therapeutic Development in Gastrointestinal Diseases	10/11	CI
Sosei Group Corporation Enters A New Oral Small Molecule Glp-1 Receptor Agonist into A Phase 1 Clinical Trial	06/11	CI
Sosei Heptares to Receive USD 3.75 Million Payment in Multi-Target Partnership	31/23/31	CI
Idorsia Pharmaceuticals Japan Ltd. Submits New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for the Approval of Daridorexant	31/23/31	CI
Sosei Group Corporation and Pharm Enable Therapeutics Expands Drug Discovery Collaboration	10/23/10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Nxera Pharma Co., Ltd.

Equities

4565

JP3431300007

Highlights

Filters